Indivior (NASDAQ:INDV) Director Mark Stejbach Acquires 775 Shares of Stock

Indivior PLC (NASDAQ:INDV) Director Mark Stejbach acquired 775 shares of the company’s stock in a transaction on Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. This trade represents a 4.82% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Indivior Price Performance

Shares of INDV stock opened at $35.89 on Thursday. Indivior PLC has a 1-year low of $7.62 and a 1-year high of $38.00. The company has a market cap of $4.49 billion, a price-to-earnings ratio of 39.01 and a beta of 0.75. The stock has a 50 day simple moving average of $33.91 and a 200-day simple moving average of $25.66.

Indivior (NASDAQ:INDV) last released its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. The firm had revenue of $314.00 million for the quarter, compared to analysts’ expectations of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. Analysts anticipate that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on INDV shares. Weiss Ratings reissued a “hold (c)” rating on shares of Indivior in a research note on Friday, October 31st. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 3rd. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a report on Wednesday, December 3rd. Piper Sandler reissued an “overweight” rating and set a $41.00 target price (up previously from $27.00) on shares of Indivior in a report on Friday, October 31st. Finally, Northland Securities set a $40.00 target price on Indivior in a research report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $32.71.

Key Stories Impacting Indivior

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: Indivior issued full‑year 2026 guidance calling for total net revenue of $1,125M–$1,195M, SUBLOCADE net revenue of $905M–$945M, non‑GAAP operating expenses of $430M–$450M, and adjusted EBITDA of $535M–$575M. The guidance implies SUBLOCADE will remain the company’s primary revenue driver and an implied adjusted EBITDA margin in the mid‑40% range, which investors view as strong profitability guidance for 2026. Indivior Provides Full-Year 2026 Financial Guidance and Business Update
• Positive Sentiment: Director David E. Wheadon purchased 1,771 shares at an average price of $35.39, increasing his stake by ~14% — a sign of insider confidence. Form 4 — David E. Wheadon
• Positive Sentiment: Directors Mark Stejbach, Daniel A. Ninivaggi, Keith Humphreys and Barbara Ryan each bought 775 shares at ~$35.39, modestly increasing their holdings; combined insider purchases across these filings total roughly 4,871 shares, signaling broad board-level conviction. Form 4 — Mark Stejbach Form 4 — Daniel A. Ninivaggi Form 4 — Keith Humphreys Form 4 — Barbara Ryan

Institutional Trading of Indivior

Large investors have recently bought and sold shares of the business. CWM LLC acquired a new stake in Indivior in the 3rd quarter valued at about $25,000. Quarry LP purchased a new stake in shares of Indivior in the third quarter valued at approximately $26,000. Raymond James Financial Inc. acquired a new stake in shares of Indivior in the second quarter valued at approximately $26,000. GAMMA Investing LLC increased its holdings in shares of Indivior by 544.6% in the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after purchasing an additional 1,013 shares during the last quarter. Finally, Plato Investment Management Ltd purchased a new position in Indivior during the third quarter worth approximately $52,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.